Currently Viewing:
ISPOR 2019
Panelists Discuss the Potential and Pitfalls of Disruption in Healthcare
May 20, 2019
Trends in Value That Dr Daniel Mullins Expects to See in Coming Years
May 21, 2019
Dr Jon Campbell Discusses the Need for More Creative Methods of Value Assessment
May 21, 2019
The Imperfect QALY: How It's Used Depends on Where You Enter Value Discussions
May 21, 2019
Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease
May 22, 2019
Panelists Debate the Role of ICER: Useful Overseer of Prices, or Oppressor of Choice?
May 22, 2019
Bringing Financial Theory Into the Value Equation of Future Cutting-Edge Therapies
May 22, 2019
Dr Devin Incerti Outlines Best Practices for Approaching Value Assessment
May 22, 2019
Biosimilar Experts Give Highlights of US Uptake Issues
May 23, 2019
Dr Nicholas Robert Explains the Benefits, Challenges of Using RWE for Measuring Clinical End Points
May 23, 2019
Dr Eleanor Perfetto Outlines Criticisms of the QALY
May 23, 2019
New Therapies Offer Possible Cures but Pose Affordability Challenges
May 23, 2019
Fremanezumab Cost Effective for Both Types of Migraine, Researchers Say
May 27, 2019
Dr Jon Campbell on Benefits of Using MCDA in Value Assessment
June 03, 2019
Dr Nicholas Robert Explains the Need to Standardize Use of RWE for Measuring Clinical End Points
June 23, 2019
Dr Devin Incerti: Use Value Assessments to Maximize the Well-Being of a Population
July 14, 2019
Dr Nicholas Robert Discusses How Real-World Data Can Complement Clinical Trial Data
July 16, 2019
Dr Eleanor Perfetto on Ways to Improve Transparency, Education Around Value Assessment
July 23, 2019
Dr Nicholas Robert on Lag Time Between Drug Approval, Availability of the Drug in EMRs
July 29, 2019
Dr Nicholas Robert: Lag Time Between a Drug Approval, Availability in EMRs Can Impact Patient Care
August 10, 2019
Currently Reading
Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs
August 22, 2019

Dr Nicholas Robert Outlines How Patients Can Provide More Information on Newly Approved Drugs

Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.


Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.

Transcript

How does real-world data’s incorporation of the patient perspective allow for confirmatory information regarding newly approved drugs? 

One of things I think real-world evidence does is that it provides confirmatory information in terms of new treatments, but also it provides the opportunity to collect the perspective of what the patient is going through. So, something that is very exciting is so-called patient-reported outcomes, and we’re developing the capacity with our EMR [electronic medical record], that not only can we describe how the patient did, talk about their response, progression, their improvement, but also we can collect their impression of how their treatment, how they’re feeling, are they have side effects? And this is coincidental with the interests and the appreciation that the better you can follow your patients, the better your patients have an opportunity to communicate with their providers, the better care is achieved. This is again a situation where incentives are aligned. At the end of the day, better improving patient care and also you can collect information as outcomes researchers to be able to share that information with others.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up